Emmaus Life Sciences (OTCMKTS:EMMA) Posts Quarterly Earnings Results

Emmaus Life Sciences (OTCMKTS:EMMA) posted its quarterly earnings data on Friday. The company reported ($0.05) EPS for the quarter, Zacks reports. The company had revenue of $1.98 million during the quarter.

Emmaus Life Sciences Price Performance

Emmaus Life Sciences stock opened at $0.01 on Friday. The company has a fifty day simple moving average of $0.01 and a 200-day simple moving average of $0.01. The firm has a market capitalization of $808,308.04, a price-to-earnings ratio of -0.09 and a beta of 9.32. Emmaus Life Sciences has a 52-week low of $0.01 and a 52-week high of $0.02.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc is a publicly traded specialty pharmaceutical company focused on the development and commercialization of therapies for sickle cell disease and other serious hematological disorders. Its lead product, Endari® (L-glutamine oral powder), received U.S. Food and Drug Administration approval in 2017 for reducing the acute complications of sickle cell disease in patients aged five years and older. Through targeted research and development, Emmaus is also advancing additional pipeline candidates aimed at addressing oxidative stress and protein aggregation pathways that underlie various blood disorders.

Emmaus markets Endari in the United States and has entered into licensing agreements to distribute the therapy in regions including sub-Saharan Africa, the Middle East, North Africa and Latin America.